# Does the extent of neck surgery based on preoperative calcitonin level influence survival in medullary thyroid carcinoma: a retrospective tertiary centre experience

**Authors:** W Ansley, A Kamyab, L Noden, B Odutoye, P Williamson, KH Wong, P Dent, A Sharma, A Weller, G Pitiyage, E Ofo

PMC · DOI: 10.1308/rcsann.2024.0033 · 2024-04-25

## TL;DR

This study examines whether preoperative calcitonin levels influence survival outcomes in medullary thyroid carcinoma patients undergoing different types of neck surgery.

## Contribution

The study provides new insights into the efficacy of using preoperative calcitonin levels to guide surgical decisions in MTC patients.

## Key findings

- No significant difference in survival was found between high and low calcitonin groups.
- Patients with high calcitonin levels did not show improved outcomes with lateral neck dissection.
- A selective approach based on clinical findings may be more effective than calcitonin-guided surgery.

## Abstract

Medullary thyroid carcinoma (MTC) is a rare thyroid cancer arising from the calcitonin-secreting parafollicular cells. Previous studies suggested a preoperative calcitonin level >200ng/l is an indication for prophylactic lateral neck dissection (LND) to remove micrometastases and improve survival outcomes.

This retrospective single-centre study assessed the efficacy of preoperative calcitonin levels as a marker for determining need for prophylactic LND in MTC. Data were obtained on demographics, preoperative calcitonin levels, size and laterality of index tumour, type of neck dissection (central neck dissection (CND), LND), nodes removed, levels with involved nodes, number of nodes histologically involved, mortality, adjuvant therapy and locoregional recurrence.

A total of 33 patients were identified from St George's University Hospitals NHS Foundation Trust between 1 January 2001 and 19 August 2021; 8 were excluded for data quality issues. Of the 18 classified with a high preoperative calcitonin level (>200ng/l), 10 (56%) had a LND and 8 (44%) had a CND. In the low-calcitonin group, three (43%) patients had a CND only and four (57%) had a LND. There was no difference in absolute or disease-free survival between the low and high groups (p=0.960, p=0.817), or between those who had a CND and LND in the high-calcitonin group (p=0.607, hazard ratio (HR) 0.55; p=0.129, HR 8.78).

There was no statistically significant difference in outcomes between high and low calcitonin groups. A selective approach to performing LND in MTC patients based on clinical and imaging findings suggesting disease presence in the lateral neck should be explored further.

## Linked entities

- **Chemicals:** calcitonin (PubChem CID 118984394)
- **Diseases:** medullary thyroid carcinoma (MONDO:0007958)

## Full-text entities

- **Genes:** CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}
- **Diseases:** tumour (MESH:D009369), CND (MESH:C535376), MTC (MESH:C536914), thyroid cancer (MESH:D013964)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11872159/full.md

---
Source: https://tomesphere.com/paper/PMC11872159